A novel tetracycline antibiotic, Sch 33256, was isolated from a culture broth of a new species of Actinomadura. The antibiotic was isolated by solvent extraction, Sephadex G-25 column chromatography and crystallization. The structure was determined by comparison of the spectra with that of chlortetracycline. Spectroscopic analysis of the compoundyielded 2'-Ar-methyl-8-methoxychlortetracycline as the proposed structure.
During the course of searching for new microbial fermentation products, a novel solvent extractable antibiotic complexhas been obtained from an organism isolated from a soil sample collected near Phoenix, Arizona. The producing culture, SCC 1676, was found to have the macroscopic, microscopic and whole-cell hydrolysis properties of the genus Actinomadura.
In this paper, we describe the fermentation, isolation and structure elucidation of the major antibiotic component Sch 33256°. Detailed taxonomy and biological properties will be reported elsewhere.
Fermentation
Fermentation studies were carried out in shake flasks and 14-liter fermentors. The inoculum for antibiotic production was prepared in a medium containing beef extract 0.3 %, Tryptone 0.5 %, yeast extract 0.5%, Cerelose 0.1 %, potato starch 2.4% and CaCQ3 0.2%. The pH of the medium was adjusted to 7.0 prior to sterilization.
A 300-ml Erlenmeyer flask containing 70 ml of this medium was inoculated with 3 ml of a stock suspension of the producing strain which had been maintained at -20°C. The flask was incubated at 30°C on a rotary shaker at 300rpm, for 48 hours. Twentyfive ml of the resulting seed culture was transferred to a 2-liter Erlenmeyer flask containing 500 ml of the above mediumand incubated as above. The entire contents were used to inoculate a 14-liter fermentor containing 10 liters of the production medium consisting of yeast extract 0.5 %, NZ-Amine 0.5%, Cerelose 1 %, soluble starch 2%, CaCO3 0.4% and 1 mMCoCl2 10 ml. The pH of the medium was adjusted to 7 before the addition of CaCO3. The fermentation was carried out at 30°C with aeration of 3.5 liters/minute and agitation at 350 rpm. The antibiotic production was monitored at regular intervals by bioassay against Staphylococcus aureus 209P and Escherichia coli A-10536. The results from the 14-liter fermentation indicated poor production and a long fermentation time (96~120 hours). To obtain a better producing isolate, strain improvement was performed using an antibiotic gradient with Sch 33256 in agar as a selective pressure as described in Fig. 1 . The parent culture was plated on agar containing a gradient of 0.0 to 1.0 mg/ml of the antibiotic complex. Eighteen colonies were picked from the 1.0 mg/ml end of the plate. These colonies were replated on a plate containing 2.0 mg/ml of antibiotic. Four colonies with good growth were picked and replated on a 10-mg/ml plate. All four colonies survived, and from these colonies one showed the most antibiotic production, as shown in Fig. 1 . Antibiotic titers were measured by bioassay against S. aureus 209P using chlortetracycline as a standard. Strain No. 4 showed a 286%-increase in antibiotic production in flasks and a 148%-increase in 14-liter tanks. The time course study for a typical 14-liter fermentation of strain No. 4 is shown in Fig. 2 . As shown, peak antibiotic titer levels were achieved in 60~70 hours as compared to 96~120 hours for the parent. The pH, dissolved oxygen, growth profile of the organism and antibiotic production were monitored.
Isolation
The whole broth (10 liters) was adjusted to pH 2 and filtered. The filtrate was adjusted to pH 8.5 and extracted two times with 10 liters of ethyl acetate. The extracts were pooled and concentrated to dryness. The active residue was dissolved in acetone and the antibiotic complex precipitated with a mixture of ether -hexane (1 :4). The resulting yellow antibiotic complex was treated with EDTAin water at pH 1.5 and extracted with methylene chloride at pH 6.5. Final purification of Sch 33256 was achieved by Sephadex G-25 column chromatography using 0.02 n HC1 as the eluting solvent2). The fractions were monitored by HPLC. The desired fractions were pooled and lyophilized. The 10 liters fermentation yielded 150 mg of pure Sch 33256.
Purity of Sch 33256 was determined by HPLC3»4)using chlortetracycline as a standard shown in Fig. 3 The high resolution (HR) EI-MS of Sch 33256 is in agreement with a molecular formula of C24H27N2O9C1.
The !H NMR (200 MHz) of Sch 33256 was found to be similar to that of chlortetracycline except for the presence of two additional methyl groups at 3.09 and 4.02 ppm. The assignment of all the carbons in the 13C NMRspectrum (50.3 MHz) of Sch 33256 and chlortetracycline is shown in the Table 25 ). The chemical shifts of most of the carbons are similar to chlortetracycline.
The major differences are in the C-7, C-8, C-9 and the two methyl groups at 56.9 and 26.5ppm.
Structure Elucidation
The physico-chemical characteristics of Sch 33256 are closely related to chlortetracycline except for the presence of NCH3and OCH3substitution. Methylation at the C-2' position was confirmed by the fragmentation pattern of the right hand part of the molecule in the EI-MS6) as shown in Fig. 4 and by the additional NCH3in the 2H NMR(at 3.09 ppm) and 13C NMR(at 26.5 ppm). Based on 2H and 13C NMR,the additional methoxy substituent can only be located on the aromatic ring at the C-8 or C-9 position. The exact location was confirmed by the chemical shifts in the 13C NMRof the C-7, C-8 and C-9 carbons when compared to chlortetracycline (Table 2 ). Further confirmation for a methoxy substituent at the C-8 position was based on the UVspectrum as compared to chlortetracycline in Fig. 5 . Chlortetracycline has an absorbance at 355 nm and Sch 33256 has an absorbance at 378 nm, which is consistent with the methoxy substituent at the C-8 position. Based on the evidence presented the structure of Sch 33256 is shown in Fig. 6 .
Biological Properties
The in vitro antibacterial activity of Sch 33256 is shown in Table 3 . Evaluation of the in vitro data showed that Sch 33256 was primarily active against Gram-positive bacteria (MICs 0.125 to 2 jLcg/ml) with significantly less activity against Gram-negative organism (16-64^g/ml). The lack of Gram-negative activity was consistent with the knownstructure activity relationship for 2'-iV-methyl substituted tetracyclines7). In summary,we have reported a novel chlortetracycline from a newspecies of Actinomadura, differing from other known tetracyclines by 8-methoxy and 2'-iV-metyl substitution. Extensive structural modification has been madeon tetracyclines including the carboxamido moiety and the C-9 position but to date no tetracycline analogs have been reported with a substituent at the C-8 position8-9).
